Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6507462 | 1.00 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL6507453 | 1.00 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL4532629 | 0.87 | MDM4 (0.52) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL31370327 | 0.84 | MDM4 (0.52) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL21639100 | 0.83 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL21639103 | 0.83 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL31694964 | 0.82 | MDM4 (0.56) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL29907962 | 0.82 | MDM4 (0.56) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL30069011 | 0.82 | MDM4 (0.56) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL3725839 | 0.82 | MDM4 (0.56) | MDM4TP53MDM2CASP3SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003959-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Bayer AS (NO) | 2022-06-01 | — | — | EP | disclosed |